GHENT, BELGIUM--(Marketwired - Apr 17, 2013) - Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from KBC Asset Management NV.
KBC Asset Management NV notified that they have exceeded the 3% threshold and now hold 1,472,009 Ablynx shares, which represent 3.03% of the current 48,505,516 outstanding shares of Ablynx.
Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
press release in pdf: http://hugin.info/137912/R/1693870/556937.pdf